Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteCurrent clinical trials testing the combination of immunotherapy with radiotherapy.Surgical immune interventions for solid malignancies.Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility.The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 MelanomaTargeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenograftsImmunocytokines for cancer treatment: past, present and future.Stromal Modulators of TGF-β in Cancer.Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen.The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.Intralesional treatment of metastatic melanoma: a review of therapeutic options.Tumor-related interleukins: old validated targets for new anti-cancer drug development.CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Targeting Fibronectin for Cancer Imaging and Therapy.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.TGF-β induces oncofetal fibronectin that, in turn, modulates TGF-β superfamily signaling in endothelial cells.Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow "in situ tumor vaccination"?Cytotoxic Activity of Oleocanthal Isolated from Virgin Olive Oil on Human Melanoma Cells.Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.Enhanced Therapeutic Activity of Non-Internalizing Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination With Targeted Interleukin-2.Zymosan attenuates melanoma growth progression, increases splenocyte proliferation and induces TLR-2/4 and TNF-α expression in mice.The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies
P2860
Q28066935-3E8C0AFF-1976-4B30-9BCE-B31118D2013AQ30356447-B975B858-B97C-4C37-8A37-63F85CFE4FFFQ30393261-A3951187-BDE5-4C87-BCA0-9040560C702BQ33829542-94E8A8B3-0017-4871-BF31-12082C19EAE2Q35924903-624E548A-68FC-4A72-9832-0727E598C160Q36545764-5DF241E0-01BF-457D-9987-9F51226F074FQ37560208-477BF9BD-D4C2-4AFB-B500-7A59F988136BQ37628179-10FD4354-1DF4-4205-8352-A8E7564FEA44Q38704265-B59B8F41-BEDF-4767-8542-A01D067CCCB6Q38716421-F35C0AE6-E1B3-422D-A49B-27216816958DQ39081034-7852D0A0-D2E0-4651-9099-0F07ECFB9644Q41716360-E729DD3C-73BC-4799-8EF2-495EB88D9B82Q44549404-536DA0A4-4A9F-45CE-8D9F-8E8156A3A061Q47221234-641DB85B-1C5B-4FD1-82F7-16B97B06026BQ47226151-F10D4AB2-51AD-4C13-AEE1-46049DB5C30FQ47277628-486968ED-2AAF-494B-BFF3-1301CAFFC065Q47329655-2A5106D3-2F7F-4E0A-9221-50DC6F77A55EQ49687675-08557834-800D-41E6-996B-27D51835EF71Q50073502-B94AC274-12C8-4F2C-A523-5F68FBCD4F33Q50885364-081F929E-1A74-42DD-AE7C-B27235CC3E57Q51059095-5DD10B58-8B03-4267-A6D4-50E3F6E94ABCQ51718381-538287B5-2F63-44C1-AD18-6BC77408FB8BQ52353493-B2BDC4BF-1CF0-48A5-BE64-C5B66EF032E8Q52565554-07AA0374-37CE-49EB-BC3E-D5FE449EBE1CQ52626634-72BA48AE-91B7-459B-B663-C53AA5112320Q52720460-A0B47743-72EE-40AB-8808-DB30AD22752BQ55316979-220E6281-A17F-422C-8497-4BF70550A779Q57201583-06C6A8E6-5ADD-458D-AAB2-10B1EAA641CA
P2860
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Intralesional administration o ...... : results of a phase II study.
@en
type
label
Intralesional administration o ...... : results of a phase II study.
@en
prefLabel
Intralesional administration o ...... : results of a phase II study.
@en
P2093
P2860
P50
P1476
Intralesional administration o ...... : results of a phase II study.
@en
P2093
Andrea Lazzeri
Anna Maria Di Giacomo
Annabella Di Florio
Carolina Fazio
Clelia Miracco
Leonardo Giovannoni
Ornella Cutaia
P2860
P2888
P304
P356
10.1007/S00262-015-1704-6
P50
P577
2015-05-14T00:00:00Z
P5875
P6179
1048148850